3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Cholangiocarcinoma
3
Liver Neoplasms
2
Biliary Tract Neoplasms
2
Acrocephalosyndactylia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Bile Duct Neoplasms
1
Interventions
pembrolizumab
92
Gemcitabine
55
Nivolumab
49
Cisplatin
38
atezolizumab
31
Carboplatin
30
avelumab
25
enfortumab vedotin
24
Docetaxel
23
Magnetic Resonance Spectroscopy
18
Ipilimumab
17
Paclitaxel
16
Mitomycin
15
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Transitional Cell
×
derazantinib
×
Clear all
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts